目标:在晚期乳腺癌中,在没有内脏危象的情况下,内分泌治疗是首选。细胞周期蛋白依赖性激酶抑制剂(CDKi)是金标准。CDKi治疗后后续治疗的选择仍存在争议,依维莫司(EVE)组合的疗效尚不清楚。在这项研究中,我们旨在研究CDKi给药后EVE在现实生活中的疗效.
方法:该研究收集了来自26个癌症中心的208名患者的数据。人口统计学和组织学特征,诊断,programming,上次访问日期,并记录毒性。本研究为回顾性病例系列。
结果:一百零七名患者接受了palbociclib,而101例患者接受ribociclib作为CDKi。EVE组合的总体反应和疾病控制率分别为60%和88%,分别。在单变量分析中,没有肝转移,年龄>40岁,更好的反应类型,CDKi术后立即治疗与无进展生存期增加相关.肝转移和应答类型与总生存率显著相关。在多变量分析中,在无进展生存期方面,反应仍然显著,而响应类型,肝转移性疾病,和血液学毒性是总生存期的预后指标.
结论:本研究提供了CDKi治疗后EVE组合的益处的证据。EVE组合可能更适合非肝转移患者,第一次治疗反应显示了治疗的益处。此外,CDKi治疗后立即治疗比后期治疗更有益.
OBJECTIVE: In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this
study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences.
METHODS: The
study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This
study was a retrospective case series.
RESULTS: One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival.
CONCLUSIONS: This
study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment.